BP 2-94

BP-2-94 is the (R)-(-)-isomer; RN given for the (R)-isomer; structure in first source

Also Known As:

(R)-2-N-1-(1H-imidazol-4-yl)-2-propyliminophenylmethylphenol; 2-((N-(1-(1H-imidazol-4-yl)-2-propyl)imino)phenylmethyl)phenol; BP 2.94; BP-2-94; BP-294

Networked: 5 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Phenols: 677
        BP 2-94: 5
- Imines: 310
  - BP 2-94: 5

Experts

1.	Schunack, W: 2 articles (04/2002 - 10/2000)
2.	Coruzzi, G: 1 article (04/2002)
3.	Grandi, D: 1 article (04/2002)
4.	Lazzaretti, M: 1 article (04/2002)
5.	Nosalova, V: 1 article (04/2002)
6.	Poli, E: 1 article (04/2002)
7.	Pozzoli, C: 1 article (04/2002)
8.	Rouleau, A: 1 article (10/2000)
9.	Schwartz, J C: 1 article (10/2000)
10.	Stark, H: 1 article (10/2000)

Related Diseases

1.	Asthma (Bronchial Asthma) 06/01/1997 - "From its pharmacokinetics and pharmacological profile BP 2-94 appears to be a promising novel therapeutic agent in disorders such as asthma, migraine or a variety of inflammatory diseases and pain associated with these disorders." 08/01/2000 - "BP-294 (a prodrug of R-alpha-methylhistamine) is a histamine-H(3) agonist under development by Bioprojet, which is currently in phase II clinical trials as a potential treatment for asthma [219798]."
2.	Pain (Aches) 06/01/1997 - "From its pharmacokinetics and pharmacological profile BP 2-94 appears to be a promising novel therapeutic agent in disorders such as asthma, migraine or a variety of inflammatory diseases and pain associated with these disorders."
3.	Migraine Disorders (Migraine) 06/01/1997 - "From its pharmacokinetics and pharmacological profile BP 2-94 appears to be a promising novel therapeutic agent in disorders such as asthma, migraine or a variety of inflammatory diseases and pain associated with these disorders."
4.	Gastric Fistula 12/01/1999 - "After intragastric administration of BP 2-94 (10 mg/kg), both the prodrug and (R)-alpha-methylhistamine were detected in plasma: plasma levels of (R)-alpha-methylhistamine decayed with a T1/2 of about 1 hr and displayed concentrations as high as 50-fold the EC50 of the drug at the H3 receptor for at least 2 hr. In conscious dogs provided with gastric fistula BP 2-94, administered at 10 and 30 mg/kg intragastrically, caused a dose-dependent inhibition (maximum reduction was about 80%) of the acid secretion stimulated by 2-deoxy-D-glucose, whereas (R)-alpha-methylhistamine (20 mg/kg, intragastrically) was ineffective. "
5.	Edema (Dropsy) 10/01/2000 - "Repeated oral administrations of BP 2-94 reduced the pre-established Freund's complete adjuvant-induced edema with an ED(50) value of 5 +/- 2 micromol/kg (p.o.) and a maximal effect of 47%. "

Related Drugs and Biologics

1.	Prodrugs
2.	alpha-methylhistamine
3.	Histamine H3 Receptors (Histamine H3 Receptor)
4.	Histamine (Histamine Dihydrochloride)
5.	Dihydrotachysterol (AT 10)
6.	Deoxyglucose (2 Deoxy D glucose)
7.	Cyclophosphamide (Cytoxan)
8.	Blood Proteins (Serum Proteins)
9.	Acids

Related Therapies and Procedures

1.	Oral Administration